Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Anila K Madiraju, Derek M Erion, Yasmeen Rahimi, Xian-Man Zhang, Demetrios T Braddock, Ronald A Albright, Brett J Prigaro, John L Wood, Sanjay Bhanot, Michael J MacDonald, Michael J Jurczak, Joao-Paulo Camporez, Hui-Young Lee, Gary W Cline, Varman T Samuel, Richard G Kibbey, Gerald I Shulman, Anila K Madiraju, Derek M Erion, Yasmeen Rahimi, Xian-Man Zhang, Demetrios T Braddock, Ronald A Albright, Brett J Prigaro, John L Wood, Sanjay Bhanot, Michael J MacDonald, Michael J Jurczak, Joao-Paulo Camporez, Hui-Young Lee, Gary W Cline, Varman T Samuel, Richard G Kibbey, Gerald I Shulman
Abstract
Metformin is considered to be one of the most effective therapeutics for treating type 2 diabetes because it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain or posing a risk of hypoglycaemia. For over half a century, this agent has been prescribed to patients with type 2 diabetes worldwide, yet the underlying mechanism by which metformin inhibits hepatic gluconeogenesis remains unknown. Here we show that metformin non-competitively inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an altered hepatocellular redox state, reduced conversion of lactate and glycerol to glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose metformin treatment effectively reduced endogenous glucose production, while increasing cytosolic redox and decreasing mitochondrial redox states. Antisense oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats resulted in a phenotype akin to chronic metformin treatment, and abrogated metformin-mediated increases in cytosolic redox state, decreases in plasma glucose concentrations, and inhibition of endogenous glucose production. These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice. These results have significant implications for understanding the mechanism of metformin's blood glucose lowering effects and provide a new therapeutic target for type 2 diabetes.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
References
- Hundal RS, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063–2069.
- Inzucchi S, MD, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Eng J Med. 1998;338:867–872.
- El-Mir M-Y, NV, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I. J Biol Chem. 2000;275:223–228.
- Owen MR, DE, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–614.
- Zhou G, MR, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174.
- Shaw RJ, LK, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–1646.
- He L, SA, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S, Wondisford FE. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137:635–646.
- Cool B, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3:403–416.
- Savage DB, CC, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, Bhanot S, Monia BP, Shulman GI. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest. 2006;116:817–812.
- Fullerton MD, GS, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, O’Neill HM, Ford RJ, Palanivel R, O’Brien M, Hardie DG, Macaulay SL, Schertzer JD, Dyck JR, van Denderen BJ, Kemp BE, Steinberg GR. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013
- Foretz M, HS, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120:2355–2369.
- Miller RA, CQ, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256–260.
- Hawley SA, GA, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002;51:2420–2425.
- Yang L, KR, Kasumov T, Zhu SH, Cendrowski AV, David F, Anderson VE, Kelleher JK, Brunengraber H. Metabolomic and mass isotopomer analysis of liver gluconeogenesis and citric acid cycle. I. Interrelation between gluconeogenesis and cataplerosis; formation of methoxamates from aminooxyacetate and ketoacids. J Biol Chem. 2008;283:21978–21987.
- Krebs HA, GT The redox state of the nicotinamide-adenine dinucleotides in rat liver homogenates. Biochem J. 1968;108:513–520.
- Williamson DH, LP, Krebs HA. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J. 1967;103:514–527.
- Bremer J, DE Studies on the active transfer of reducing equivalents into mitochondria via the malate-aspartate shuttle. Biochim Biophys Acta. 1975;376:387–397.
- Cederbaum AI, LC, Beattie DS, Rubin E. Characterization of shuttle mechanisms for the transport of reducing equivalents into mitochondria. Arch Biochem Biophys. 1973;158:763–781.
- Garrib A, MW Purification and Characterization of Glycerol-3-phosphate Dehydrogenase (Flavin-linked) from Rat Liver Mitochondria. J Biol Chem. 1986;261:8042–8048.
- Cole ES, LC, Holohan PD, Fondy TP. Isolation and characterization of flavin-linked glycerol-3-phosphate dehydrogenase from rabbit skeletal muscle mitochondria and comparison with the enzyme from rabbit brain. J Biol Chem. 1978;253:7952–7959.
- White HB, 3rd, KN Purification and properties of two types of diphosphopyridine nucleotide-linked glycerol 3-phosphate dehydrogenases from chicken breast muscle and chicken liver. J Biol Chem. 1969;244:6031–6039.
- Sistare FD, HR The Interaction between the Cytosolic Pyridine Nucleotide Redox Potential and Gluconeogenesis from Lactate/Pyruvate in Isolated Rat Hepatocytes. J Biol Chem. 1985;260:12748–12753.
- Sugano T, SM, Tanaka T, Miyamae Y, Shimada M, Oshino N. Intracellular redox state and stimulation of gluconeogenesis by glucagon and norepinephrine in the perfused rat liver. J Biochem. 1980;87:153–166.
- MacDonald MJ, ML Mouse lacking NAD+-linked glycerol phosphate dehydrogenase has normal pancreatic beta cell function but abnormal metabolite pattern in skeletal muscle. Arch Biochem Biophys. 2000;384:143–153.
- Prochazka M, KU, Kozak LP. A glycerol-3-phosphate dehydrogenase null mutant in BALB/cHeA mice. J Biol Chem. 1989;264:4679–4683.
- Harding JW, Jr, PE, Copeland ES, White HB., 3rd Role of glycerol 3-phosphate dehydrogenase in glyceride metabolism. Effect of diet on enzyme activities in chicken liver. Biochem J. 1975;146:223–229.
- Harding JW, Jr, PE, Morris HP, White HB., 3rd Proportional activities of glycerol kinase and glycerol 3-phosphate dehydrogenase in rat hepatomas. Biochem J. 1975;148:545–550.
- Brown LJ, KR, Everett C, Reitman ML, Marshall L, Fahien LA, Kozak LP, MacDonald MJ. Normal thyroid thermogenesis but reduced viability and adiposity in mice lacking the mitochondrial glycerol phosphate dehydrogenase. J Biol Chem. 2002;277:32892–32898.
- Barberà A, GM, Eto K, Corominola H, Maechler P, Miró O, Cardellach F, Gomis R. A high carbohydrate diet does not induce hyperglycaemia in a mitochondrial glycerol-3-phosphate dehydrogenase-deficient mouse. Diabetologia. 2003;46:1394–1401.
- Colussi T, PD, Boles W, Matsuoka T, Mallett TC, Karplus PA, Claiborne A. Structure of alpha-glycerophosphate oxidase from Streptococcus sp.: a template for the mitochondrial alpha-glycerophosphate dehydrogenase. Biochemistry. 2008;47:965–977.
- Faupel RP, SH, Tarnowski W, Thiemann V, Weiss C. The problem of tissue sampling from experimental animals with respect to freezing technique, anoxia, stress and narcosis. A new method for sampling rat liver tissue and the physiological values of glycolytic intermediates and related compounds. Arch Biochem Biophys. 1972;148:509–522.
- Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GIW, DH, McGuinness OP NIH Mouse Metabolic & Consortium PC . Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3:525–534.
- Carmignani M, VA, Botta B, Espinal R, De Bonnevaux SC, De Luca C, Botta M, Corelli F, Tafi A, Sacco R, Delle Monache G. Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues. J Med Chem. 2001;44:2950–2958.
Source: PubMed